NEW YORK (GenomeWeb) – Qiagen said today that it has initiated a clinical development program with Novartis for a molecular companion diagnostic to guide the use of a Novartis investigational PI3K inhibitor in certain breast cancer patients.

Specifically, the proposed CDx would guide use of Novartis' BYL719 (alpelisib) in combination with fulvestrant for men and postmenopausal women with PIK3CA-mutated, hormone receptor-positive, EGFR receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Feb
26
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease.